Tiagabine – kdc

CLINICAL USE

Anti-epileptic agent

DOSE IN NORMAL RENAL FUNCTION

15–45 mg daily in 3 divided doses if dose >30 mg

PHARMACOKINETICS

Molecular weight : 412

%Protein binding : 96

%Excreted unchanged in urine : <2

Volume of distribution (L/kg) : 1

half-life – normal/ESRD (hrs) : 7–9 (2–3 in patients on enzyme inducing drugs)

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD : Unknown dialysability. Dose as in normal renal function

HD : Not dialysed. Dose as in normal renal function

HDF/high flux : Unknown dialysability. Dose as in normal renal function

CAV/VVHD : Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antidepressants: antagonism of anticonvulsant effect (convulsive threshold lowered)

Anti-epileptics: concentration reduced by phenytoin, carbamazepine, phenobarbital and primidone

Antimalarials: mefloquine antagonises anticonvulsant effect; chloroquine and hydroxychloroquine occasionally reduce convulsive threshold

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Although there is no evidence of withdrawal seizures, it is recommended to taper off treatment over a period of 2–3 weeks .

Tags: post-by-auto-php